PTCT241220P38000
- 4.20
- 0.000.00%
PTC Therapeutics Newsroom
PTC Therapeutics (NASDAQ:PTCT) Delivers Shareholders Notable 96% Return Over 1 Year, Surging 7.5% in the Last Week Alone
RBC Capital Remains a Hold on PTC Therapeutics (PTCT)
PTC Therapeutics ALS Drug Fails to Meet Endpoints as Trials Shut Down
Baird Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $52
Baird Maintains Outperform on PTC Therapeutics, Raises Price Target to $52
PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs
TD Cowen Remains a Hold on PTC Therapeutics (PTCT)
PTC Therapeutics Enters Into Agreement to Sell Priority Review Voucher for $150 Million
BofA Securities Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Announces Target Price $31
PTC Therapeutics: Sell Rating Due to Unmet Trial Goals and Overvaluation Concerns
William Blair Maintains PTC Therapeutics(PTCT.US) With Buy Rating
PTC Therapeutics: Growth Potential Amid Strategic Shifts and Upcoming Catalysts
PTC Therapeutics' Amyotrophic Lateral Sclerosis Trial Fails to Meet Endpoints; Shares Fall After Hours
PTC Therapeutics to End Development of ALS Treatment
PTC Therapeutics: Phase 2 CardinALS Study Did Not Meet Its Primary Endpoint
Express News | PTC Therapeutics Inc - Further Development of Utreloxastat Not Planned
Express News | PTC Therapeutics Inc - Study Failed to Meet Primary and Secondary Efficacy Endpoints
Express News | PTC Therapeutics Announces Topline Results of Cardinals Trial of Utreloxastat in ALS Patients
PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients
Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $68